Hindalco Industries, Sun Pharma, BPCL, UltraTech Cement and HDFC Bank gained the most on the Nifty, while losers included Bharti Airtel, Cipla, Divis Labs, Apollo Hospitals and HUL
Monte Carlo Fashions maintains its yearly growth guidance of 20-25 percent as mentioned earlier.
Catch all the market highs and lows with Yatin Mota only on Moneycontrol.
The company announced issuance of convertible warrants worth Rs 372 crore to promoter and OrbiMed Asia
The board of directors approved the issuance of non-convertible debentures (NCD) on private placement basis for an amount not exceeding Rs 700 crore
Net Sales are expected to increase by 10.1 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 922 crore, according to Sharekhan.
Net Sales are expected to increase by 20 percent Y-o-Y (up 11.1 percent Q-o-Q) to Rs. 344 crore, according to Sharekhan.
Net Sales are expected to increase by 19.1 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 1,331 crore, according to Sharekhan.
Net Sales are expected to increase by 7 percent Y-o-Y (up 4 percent Q-o-Q) to Rs. 374 crore, according to Sharekhan.
Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.1 percent Q-o-Q) to Rs. 436 crore, according to Sharekhan.
Rail Vikas Nigam has been asked to build an elevated viaduct and nine elevated metro stations
ICICI Securities is bullish on Gokaldas Exports recommended buy rating on the stock with a target price of Rs 560 in its research report dated January 11, 2022.
ICICI Securities is bullish on Syrma SGS Technology recommended buy rating on the stock with a target price of Rs 350 in its research report dated January 11, 2022.
Zomato’s focus on growth may lead to delays in its short-run profitability targets but strategic initiatives hold the possibility of building a more sustainable business model with high-quality growth
Although Nykaa is showing profitability, the business fundamentals look challenging as it faces competition in the BPC and fashion segments. A faster turnaround in the fashion segment and strategic initiatives may provide optimism to investors.
The US drugs regulator conducted pre-approval inspection and good manufacturing practices inspection of the company's Lexington facility from December 27 to January 10
Net Sales are expected to increase by 1.7 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 1,121 crore, according to Sharekhan.
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs. 1,123 crore, according to Sharekhan.
Net Sales are expected to decrease by 1.9 percent Y-o-Y (down 8.5 percent Q-o-Q) to Rs. 1,909 crore, according to Sharekhan.
Net Sales are expected to increase by 53.8 percent Y-o-Y (up 13 percent Q-o-Q) to Rs. 677 crore, according to Sharekhan.
Net Sales are expected to increase by 19.9 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 3,872 crore, according to Sharekhan.
Net Sales are expected to increase by 7.5 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 3,066 crore, according to Sharekhan.
Net Sales are expected to decrease by 2.4 percent Y-o-Y (down 8 percent Q-o-Q) to Rs. 828 crore, according to Sharekhan.
Net Sales are expected to increase by 14.8 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs. 516 crore, according to Sharekhan.
Net Sales are expected to increase by 0.4 percent Y-o-Y (down 32.8 percent Q-o-Q) to Rs. 1,940.1 crore, according to HDFC Securities.